Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking 

Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context

Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit 

Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.